<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01045980</url>
  </required_header>
  <id_info>
    <org_study_id>SJH-Renal-RCT-003</org_study_id>
    <nct_id>NCT01045980</nct_id>
  </id_info>
  <brief_title>Effect of Bio-impedance Analysis and Vitamin D vs Usual Care on Left Ventricular Mass in Peritoneal Dialysis Patients: A Randomized Controlled Trial (FLUID Study)</brief_title>
  <acronym>FLUID</acronym>
  <official_title>The Effect of Bio-impedance Analysis and Vitamin D Versus Usual Care on Left Ventricular Mass in Peritoneal Dialysis Patients: a Randomized Controlled Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>St. Joseph's Healthcare Hamilton</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Population Health Research Institute</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>St. Joseph's Healthcare Hamilton</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The main purpose of this study is to compare the effects of using bio-impedance analysis to
      guide management of fluid status versus routine clinical care on heart structure. In
      addition, Vitamin D is being assessed to determine its effect on heart structure.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients on peritoneal dialysis are frequently hypervolemic which is associated with
      deleterious changes in left ventricular (LV) architecture including increased LV mass. In
      dialysis patients, increased LV mass is associated with death. Recent randomized trials have
      demonstrated that increasing small solute clearance is not associated with improved outcomes
      - hence an increased interest in the management of volume control in ESRD patients.
      Bioimpedance analysis is inexpensive, safe and easy to use and appears to be more useful than
      other techniques to assess volume status in dialysis patients. In addition, dialysis patients
      are vitamin D deficient and this is also associated with an increased LV mass and its
      inherent complications.

      This study will evaluate the use of bioimpedance analysis versus usual care to assess and
      manage volume status and the use of vitamin D versus placebo in peritoneal dialysis patients
      and its effect on LV mass as measured by cardiac MRI.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>August 2010</start_date>
  <completion_date type="Anticipated">August 2015</completion_date>
  <primary_completion_date type="Anticipated">August 2014</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Factorial Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Left ventricular mass measured by cardiac MRI</measure>
    <time_frame>1 year</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Combined outcome of death, non-fatal CV event (stroke, MI, amputation, CHF), and transfer to HD for inadequacy or ultrafiltration failure</measure>
    <time_frame>3 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Volume measures: bio-impedance (RXc graph, vector length, impedance ratio, phase angle, ECW:TBW ratio), weight, N-BNP, mean and pulse arterial pressure, number of anti-hypertensive agents</measure>
    <time_frame>3 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Health-related quality of life (HRQOL)</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Physical function as measured by 6 minute walk test</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum and peritoneal inflammatory and fibrotic markers: albumin, CRP, IL-6, TNF-a</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Peritoneal membrane transport properties,measured by PET</measure>
    <time_frame>3 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Renal and peritoneal solute clearance, 24-hour urine output and ultrafiltration volume</measure>
    <time_frame>3 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>left ventricular end-diastolic and systolic volumes, stroke volume and ejection fraction measure by MRI</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fraility Score</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">70</enrollment>
  <condition>Peritoneal Dialysis</condition>
  <arm_group>
    <arm_group_label>Bioimpedance and Vitamin D</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Usual care and Vitamin D</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Vitamin D3</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Bioimpedance and Placebo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Usual Care and Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bioimpedance and Vitamin D</intervention_name>
    <description>Intervention subjects will undergo BIA assessment monthly for 1 year, and then every 3 months until the end of the planned 3-year study. Protocolized interventions to achieve euvolemia will occur based on the BIA result and they include sodium restriction, addition of diuretics, use of icodextrin, and additional rational changes to the PD prescription.</description>
    <arm_group_label>Bioimpedance and Vitamin D</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Usual care and placebo</intervention_name>
    <description>Usual care (not bioimpedance guided volume management) and Placebo</description>
    <arm_group_label>Usual Care and Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Usual care and Vitamin D</intervention_name>
    <description>Usual care (not bioimpedance guided volume management) and Vitamin D</description>
    <arm_group_label>Usual care and Vitamin D</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Bioimpedance and Placebo</intervention_name>
    <description>Bioimpedance guided volume management and Placebo</description>
    <arm_group_label>Bioimpedance and Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age â‰¥18 years

          -  on peritoneal dialysis

        Exclusion Criteria:

          -  Contraindication to MRI including presence of a pacemaker, defibrillator,
             ferromagnetic cerebral aneurysm clips, cochlear implants or eye prosthesis,
             neurostimulators, shrapnel in vital locations, surgery within 6 weeks, severe
             claustrophobia and severe obesity

          -  Previous amputation

          -  Life or technique expectancy &lt; 1 year

          -  Pregnancy

          -  Peritonitis in previous 3 months

          -  Currently using more than one extraneal bag per 24-hours

          -  Known icodextrin allergy

          -  Currently using non-Baxter PD solutions

          -  Inability to provide consent

          -  Allergy to cholecalciferol

          -  Serum Calcium &gt; 2.55 mmol/L
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Azim S Gangji, MD MSc FRCPC</last_name>
    <role>Principal Investigator</role>
    <affiliation>St. Joseph's Healthcare Hamilton</affiliation>
  </overall_official>
  <overall_official>
    <last_name>K S Brimble, MD MSc FRCPC</last_name>
    <role>Principal Investigator</role>
    <affiliation>St. Joseph's Healthcare Hamilton</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Dr. Azim S Gangji, MD MSc FRCPC</last_name>
    <phone>9055221155</phone>
    <phone_ext>33261</phone_ext>
    <email>gangji@mcmaster.ca</email>
  </overall_contact>
  <location>
    <facility>
      <name>St. Joseph's Healthcare Hamilton</name>
      <address>
        <city>Hamilton</city>
        <state>Ontario</state>
        <zip>L8N4A6</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Azim Gangji, MD MSc FRCPC</last_name>
      <phone>(905)522-1155</phone>
      <phone_ext>33261</phone_ext>
      <email>gangji@mcmaster.ca</email>
    </contact>
    <contact_backup>
      <last_name>Scott Brimble, MD MSc FRCPC</last_name>
      <phone>(905)522-1155</phone>
      <email>brimbles@mcmaster.ca</email>
    </contact_backup>
    <investigator>
      <last_name>Azim Gangji, MD MSc FRCPC</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>K S Brimble, MD MSc FRCPC</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Catherine M Clase, MD MSc FRCPC</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Peter Margetts, MD PhD FRCPC</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Winnie S Su, MD FRCPC</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Population Health Research Institute - McMaster University</name>
      <address>
        <city>Hamilton</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <link>
    <url>http://www.hamiltonkidneyresearch.ca/</url>
    <description>Hamilton Centre for Kidney Research</description>
  </link>
  <verification_date>June 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 8, 2010</study_first_submitted>
  <study_first_submitted_qc>January 8, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 11, 2010</study_first_posted>
  <last_update_submitted>December 10, 2013</last_update_submitted>
  <last_update_submitted_qc>December 10, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 11, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Peritoneal dialysis</keyword>
  <keyword>Impedance, bioelectric</keyword>
  <keyword>Hypertrophy, left ventricular</keyword>
  <keyword>Fluid status</keyword>
  <keyword>Volume overload</keyword>
  <keyword>Congestive heart failure</keyword>
  <keyword>Cardiovascular outcomes</keyword>
  <keyword>Randomized controlled trial</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vitamins</mesh_term>
    <mesh_term>Vitamin D</mesh_term>
    <mesh_term>Ergocalciferols</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

